These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36921204)

  • 21. Second dose of measles-mumps-rubella-varicella vaccine (MMRV) and the risk of febrile convulsions.
    Schäfer W; Reinders T; Schink T
    Vaccine; 2022 Mar; 40(14):2168-2172. PubMed ID: 35232594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P; Lim FS; Han HH; Willems P
    Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy.
    Durando P; Esposito S; Bona G; Cuccia M; Desole MG; Ferrera G; Gabutti G; Pellegrino A; Salvini F; Henry O; Povey M; Marchetti F
    Vaccine; 2016 Aug; 34(36):4278-84. PubMed ID: 27423382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of the combined vaccine for measles, mumps, and rubella isolated or combined with the varicella component administered at 3-month intervals: randomised study.
    Santos EMD; Noronha TG; Alves IS; Cruz RLS; Ferroco CLV; Brum RC; Oliveira PMN; Siqueira MM; Lima MC; Ramos FLP; Bragagnolo CM; Camacho LAB; Maia MLS
    Mem Inst Oswaldo Cruz; 2019 Mar; 114():e180517. PubMed ID: 30843921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 26. Childhood vaccination coverage of hepatitis A, measles, mumps and rubella, and varicella: temporal trend analysis in Minas Gerais, Brazil.
    Oliveira GCCF; Rodrigues RN; Silva MCD; Nascimento GLMD; Lanza FM; Gusmão JD; Oliveira VC; Guimarães EAA
    Rev Bras Epidemiol; 2022; 25():e220010. PubMed ID: 35544837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolution of vaccines for early childhood: the MMRV.
    Ferrera G; Squeri R; Genovese C
    Ann Ig; 2018; 30(4 Supple 1):33-37. PubMed ID: 30062378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
    Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
    Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
    Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Varicella vaccines and measles, mumps, rubella, and varicella vaccine.
    Bricks LF; Sato HK; Oselka GW
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S101-8. PubMed ID: 16826308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients.
    Feldman AG; Beaty BL; Ferrolino JA; Maron G; Weidner HK; Ali SA; Bitterfeld L; Boulware MA; Campbell KM; Carr E; Chapman S; Chang YC; Cunningham R; Dallas RH; Dantuluri KL; Domenick BN; Ebel NH; Elisofon S; Fawaz R; Foca M; Gans HA; Gopalareddy VV; Gu C; Gupta NA; Harmann K; Hollenbeck J; Huppler AR; Jaramillo C; Kasi N; Kerkar N; Lerret S; Lobritto SJ; Lopez MJ; Marini E; Mavis A; Mehra S; Moats L; Mohandas S; Munoz FM; Mysore KR; Onsan C; Ovchinsky N; Perkins K; Postma S; Pratscher L; Rand EB; Rowe RK; Schultz D; Sear K; Sell ML; Sharma T; Stoll J; Vang M; Villarin D; Weaver C; Wood P; Woodford-Berry O; Yanni G; Danziger-Isakov LA
    JAMA Netw Open; 2023 Oct; 6(10):e2337602. PubMed ID: 37824141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital.
    Kanamori H; Tokuda K; Ikeda S; Endo S; Ishizawa C; Hirai Y; Takahashi M; Aoyagi T; Hatta M; Gu Y; Yano H; Weber DJ; Kaku M
    Tohoku J Exp Med; 2014 Oct; 234(2):111-6. PubMed ID: 25224029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.
    Platt H; Tochihara S; Oda Y; Ueda K
    Jpn J Infect Dis; 2021 Sep; 74(5):429-436. PubMed ID: 33518626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12-15 months: A phase III, randomized, non-inferiority trial.
    MMR-161 Study Group
    Vaccine; 2018 Sep; 36(38):5781-5788. PubMed ID: 30104117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children.
    Yetman RJ; Shepard JS; Duke A; Stek JE; Petrecz M; Klopfer SO; Kuter BJ; Schödel FP; Lee AW
    Hum Vaccin Immunother; 2013 Aug; 9(8):1691-7. PubMed ID: 23744509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
    Ma SJ; Li X; Xiong YQ; Yao AL; Chen Q
    Medicine (Baltimore); 2015 Nov; 94(44):e1721. PubMed ID: 26554769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.